{"id":"W2127018518","doi":"10.1016/s1470-2045(15)70128-2","title":"Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":335,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Jewish General Hospital","funders":"Genentech","keywords":"Medicine; Internal medicine; Tolerability; Brentuximab vedotin; Rituximab; Antibody-drug conjugate; Oncology; Refractory (planetary science); Lymphoma; Phases of clinical research; Adverse effect; Clinical trial; Antibody; Immunology; Monoclonal antibody; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058445,0.0008171954,0.001485348,0.0003135106,0.0002344712,0.0009967886,0.0006406475,0.0009847456,0.001537749],"category_scores_gemma":[0.000905818,0.0004201226,0.0009369723,0.0003012556,0.0008794629,0.0007891159,0.0002214299,0.00184855,0.000428045],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008975232,"about_ca_system_score_gemma":0.0006194409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006323617,"about_ca_topic_score_gemma":0.001011835,"domain_scores_codex":[0.999622,0.0001808356,0.00001715175,0.00006807265,0.00004223931,0.00006978019],"domain_scores_gemma":[0.9993914,0.0001724193,0.0001475913,0.00005706667,0.00002939693,0.000202082],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7530681,0.03418594,0.01022002,0.0008576541,0.001769622,0.0003909985,0.0003420066,0.003074639,0.05451124,0.0003544275,0.001877587,0.1393478],"study_design_scores_gemma":[0.4001138,0.5627787,0.02453969,0.00005161968,0.0009065569,0.0006459692,0.00009955259,0.001633745,0.005668128,0.0003602722,0.003157291,0.00004474709],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972179,0.001681134,0.00013018,0.00008694255,0.00003003623,0.0001853178,0.0002034534,0.00001648297,0.0004484115],"genre_scores_gemma":[0.9970252,0.001220973,0.0001734966,0.0001714943,0.00005045387,0.0001823204,0.0004294196,0.00001256668,0.0007340094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001537749,"threshold_uncertainty_score":0.006512046,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03697546453452785,"score_gpt":0.3523724593174217,"score_spread":0.3153969947828939,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}